Chemomab (CMMB) postpones 2026 Annual General Meeting after lack of quorum
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Chemomab Therapeutics Ltd. has adjourned its Annual General Meeting of Shareholders due to a lack of quorum. The meeting, originally scheduled for April 28, 2026 in Ramat Gan, Israel, has been postponed to May 5, 2026 at the same time and location.
The agenda and proposed resolutions remain as set out in the proxy statement furnished on March 20, 2026, which continues to govern the matters to be voted on. This report is also incorporated by reference into Chemomab’s existing Form F-3 and Form S-8 registration statements.
Positive
- None.
Negative
- None.
Key Figures
Original AGM date: April 28, 2026
Adjourned AGM date: May 5, 2026
Proxy statement filing date: March 20, 2026
3 metrics
Original AGM date
April 28, 2026
Initial Annual General Meeting date in Israel
Adjourned AGM date
May 5, 2026
New date for Annual General Meeting after adjournment
Proxy statement filing date
March 20, 2026
Date Chemomab furnished Form 6-K with proxy statement
Key Terms
Annual General Meeting of Shareholders, lack of quorum, proxy statement, Registration Statements on Form F-3, +1 more
5 terms
lack of quorum regulatory
"to Tuesday, May 5, 2026 ... due to a lack of quorum"
proxy statement regulatory
"including a proxy statement, which includes the full version of the proposed resolutions"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
Registration Statements on Form F-3 regulatory
"incorporated by reference into the Company’s Registration Statements on Form F-3"
Form S-8 regulatory
"Registration Statements on Form F-3 ... and Form S-8"
A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.
FAQ
Why did Chemomab Therapeutics (CMMB) adjourn its 2026 Annual General Meeting?
Chemomab adjourned its 2026 Annual General Meeting because there was a lack of quorum at the originally scheduled session. Without sufficient shareholder participation, the company could not legally conduct votes on the proposed resolutions outlined in its previously distributed proxy statement.
When will Chemomab Therapeutics (CMMB) hold the adjourned Annual General Meeting?
The adjourned Annual General Meeting is scheduled for May 5, 2026, at 4:30 p.m. Israel time. It will take place at Meitar Law Offices in Ramat Gan, Israel, at the same venue and time as initially planned for the original April 28, 2026 meeting.
How does this Form 6-K affect Chemomab’s Form F-3 and Form S-8 registrations?
This Form 6-K is incorporated by reference into Chemomab’s Form F-3 and Form S-8 registration statements. Incorporation by reference means the information about the adjourned meeting becomes part of those registration documents for U.S. securities law disclosure purposes.
Where is Chemomab’s adjourned Annual General Meeting being held?
The adjourned Annual General Meeting will be held at Meitar Law Offices, 16 Abba Hillel Road, 10th floor, Ramat Gan, Israel. The company confirmed that the location and time remain unchanged from the original April 28, 2026 meeting notice to shareholders.